Emil D. Kakkis - Oct 19, 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
President & CEO, Director
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Oct 19, 2023
Transactions value $
-$1,275,761
Form type
4
Date filed
10/23/2023, 05:14 PM
Previous filing
Mar 3, 2023
Next filing
Jan 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Options Exercise $328K +47.9K +7.99% $6.86* 647K Oct 19, 2023 Direct F1
transaction RARE Common Stock Sale -$1.6M -47.9K -7.39% $33.52 600K Oct 19, 2023 Direct F2, F3, F4
holding RARE Common Stock 2.26M Oct 19, 2023 By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RARE Stock Option (Right to Buy) Options Exercise $0 -47.9K -100% $0.00* 0 Oct 19, 2023 Common Stock 47.9K $6.86 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $34.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Includes 567 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023.
F4 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F5 The option vested with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares thereafter such that the option fully vested on the fourth anniversary of the grant date.